Kailera Therapeutics Inc KLRA
News
Kailera Reports Third Quarter 2026 Financial Results and Provides Business Updates
Kailera Therapeutics to Participate in November Investor Conferences
Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting
Kailera Therapeutics Announces Completion of Enrollment in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide Injection
Kailera Therapeutics to Participate in September Investor Conferences
